Animal models of Alzheimer’s disease (AD) are invaluable in dissecting the pathogenic mechanisms and assessing the efficacy of potential new therapies. Here, we used the peroxisome proliferator-activated receptor gamma agonist pioglitazone in an attempt to rescue the pathogenic phenotype in adult (12 months) and aged (>18 months) bitransgenic A/T mice that overexpress a mutated human amyloid precursor protein (APPSwe,Ind) and a constitutively active form of transforming growth factor-β1 (TGF-β1). A/T mice recapitulate the AD-related cognitive deficits, amyloid beta (Aβ) and cerebrovascular pathologies, as well as the altered metabolic and vascular coupling responses to increased neuronal activity. Pioglitazone normalized neurometabolic and neurovascular coupling responses to sensory stimulation, and reduced cortical astroglial and hippocampal microglial activation in both age groups. Spatial learning and memory deficits in the Morris water maze were not rescued by pioglitazone, but reversal learning was improved in the adult cohort notwithstanding a progressing Aβ pathology. While pioglitazone preserved the constitutive nitric oxide synthesis in the vessel wall, it unexpectedly failed to restore cerebrovascular reactivity in A/T mice and even exacerbated the dilatory deficits. These data demonstrate pioglitazone’s efficacy on selective AD hallmarks in a complex AD mouse model of comorbid amyloidosis and cerebrovascular pathology. They further suggest a potential benefit of pioglitazone in managing neuroinflammation, cerebral perfusion and glucose metabolism in AD patients devoid of cerebrovascular pathology.
Citation: Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E (2013) Pioglitazone Improves Reversal Learning and Exerts Mixed Cerebrovascular Effects in a Mouse Model of Alzheimer’s Disease with Combined Amyloid-β and Cerebrovascular Pathology. PLoS ONE 8(7): e68612. https://doi.org/10.1371/journal.pone.0068612
Editor: Stephen D Ginsberg, Nathan Kline Institute and New York University School of Medicine, United States of America
Received: February 8, 2013; Accepted: May 31, 2013; Published: July 18, 2013
Copyright: © 2013 Papadopoulos et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Canadian Institutes of Health Research (CIHR grant MOP-84275 to EH) and Takeda Pharmaceuticals U.S.A., Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. These funding sources do not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Competing interests: The authors have declared that no competing interests exist.
Alzheimer’s disease (AD), the most common form of senile dementia in the elderly, is characterized by increased levels of amyloid-β (Aβ) peptide and neurofibrillary tangles, and by neuroinflammation. It is also marked by early decreases in cerebral glucose uptake (CGU) and cerebral blood flow (CBF), and by a cerebrovascular pathology . The latter is multifaceted and involves a vascular fibrosis with thickening of the basement membrane, which has been imputed to increased levels of transforming growth factor-β1 (TGF-β1) [2–4]. Hence, in order to better recapitulate the complexity of the AD pathology, a double transgenic mouse model that concurrently overproduces Aβ and TGF-β1 (A/T mice) has been characterized . A/T mice display the broad spectrum of cerebrovascular, neuronal, glial, and cognitive alterations found in AD patients, thereby integrating the comorbid factor of cerebrovascular pathology to that of increased amyloidosis in the pathogenesis of AD .
Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPARγ) agonist that remains a potential candidate for AD therapy [7,8]. This interest was originally sparked by pioglitazone’s ability to cross the blood-brain-barrier (BBB)  and subsequent findings of its benefits against multiple features of AD pathology. In mice overexpressing mutated human amyloid precursor protein (APP mice), pioglitazone reduced glial inflammation, normalized CGU and cerebrovascular function, despite limited or no effect on Aβ processing and deposition [10–12]. Pioglitazone was similarly effective in restoring CGU and cerebrovascular function in mice that overexpress TGF-β1 [13,14], faithfully reproducing the AD cerebrovascular pathology . However, further testing of pioglitazone therapy in AD might gain from a thorough examination of its efficacy in a more complex model, such as the A/T mice.
Hence, we investigated the effects of pioglitazone in adult and aged A/T mice on AD hallmarks including impaired neuronally-induced CGU and CBF responses, glial activation, amyloidosis and hippocampus-based learning and memory deficits. Cerebral arterial responsiveness and proteins regulating vascular structure or function were also evaluated. Despite aggravating effects of pioglitazone on vasodilatory responses, our findings support the use of pioglitazone as a strategy to delay the progression of the disease, particularly in AD patients free of vascular diseases, by demonstrating efficacy on AD-related neuroinflammation, hypoperfusion and hypometabolism together with benefits on cognitive flexibility.
A/T mice  overexpress a mutated form of the human amyloid precursor protein (APPSwe,Ind) driven by the platelet-derived growth factor β promoter (line J20)  and a constitutively active form of TGF-β1 under the control of the glial fibrillary acidic protein (GFAP) promoter on a C57BL/6J background (line T64) . The expression of both transgenes was identified by touchdown PCR using tail-extracted DNA . Adult (12 months old at endpoint; treated for 6 months, N=8-11/group) and aged (18-21 months old at endpoint; treated for 3 months N=5-7/group) A/T mice and wild-type (WT) littermates (body weight, ~30-60g) were treated or not with pioglitazone (20mg/kg/day in chow) with males and females evenly distributed in each group. Water and chow were available ad libitum. At the end of treatment, pioglitazone treated-A/T mice of both cohorts had gained more weight compared to age-matched WT or untreated A/T mice [adult (g): WT: 12.5 ± 1.0; WTpio: 8.6 ± 0.9; A/T: 11.7 ± 0.9; A/Tpio 21.6 ± 1.1; p<0.05; aged (g): WT: 2.5 ± 1.5; WTpio: 5.2 ± 2.3; A/T: 2.6 ± 0.5 vs A/Tpio 10.0 ± 0.9; p<0.05]. Fasting glycemia measured with a commercial glucometer (One Touch Ultra, LifeScan, Burnaby, BC, Canada) using blood collected from the mouse’s tail vein was not altered by treatment at any age [adult (mmol/L): WT 9.5 ± 0.4, WTpio 9.0 ± 0.3, A/T 8.7 ± 0.5, A/Tpio 8.8 ± 0.4; aged (mmol/L): WT 9.5 ± 0.5; WTpio 8.8 ± 0.3; A/T 9.2 ± 0.3; A/Tpio 8.4 ± 0.2]. All experiments were approved by the Animal Ethics Committee of the Montreal Neurological Institute, and abided by the guidelines of the Canadian Council on Animal Care.
Morris Water Maze. (i) Spatial Learning and Memory. Mice were trained to escape onto a platform located in a circular pool (1.4 m diameter) filled with opaque water (18±1°C) and located in a room with visual wall cues. The pool was subdivided into four quadrants numbered in a clockwise order – quadrant 1 being located north-east. There were two platform locations: (1) the visible platform (original quadrant; south-east quadrant 2) for a three-day training session, and (2) the hidden platform (target quadrant; north-west quadrant 4) submerged ~1cm below the surface of the water for a five-day training session. The location of the distal wall cues was randomly changed between the visible and hidden platform sessions, as previously described . Mice were given three trials daily (spaced 45min apart) with a maximum duration of 60s/trial and 90s/trial for the visible and hidden platform training sessions, respectively. On the first day of each session, mice that failed to locate the platform in the allotted time were guided to and allowed to stay on it for 10s. Spatial memory was tested during the probe trial (60s, platform removed) 24h after the last hidden platform trial (day 9). Mice were kept warm with a heating lamp and testing began at the same time every day. Escape latencies and probe trial measures were recorded with the 2020 Plus tracking system and Water 2020 software (Ganz FC62D video camera; HVS Image, Buckingham, UK) . The parameters of the probe trial were: percent time spent and distance traveled in target quadrant, average distance to platform location (the Gallagher measure ) and swim speed. The probe trial analysis was additionally subdivided in temporal patterns of search in the target quadrant presented in slices of 15s each .
(ii) Cognitive flexibility. The inability to switch to a new platform location while failing to suppress the execution of a previously learned task is a correlate of impaired cognitive flexibility [19,20]. To examine such possible alterations, the probe trial analysis was further extended to the assessment of the same abovementioned parameters in the original quadrant. Subsequent experiments resumed 2 days later.
Cerebral glucose uptake (CGU)
This test was performed only in mice from the aged cohort. Mice were fasted for 12h before being scanned for CGU of 2-deoxy-2-[18F] fluoro-D-glucose ([18F] FDG) under isoflurane (1–2% in medical air) anesthesia in a CTI Concorde R4 micropositron emission tomography (microPET) scanner (Siemens Preclinical Solutions, Knoxville, TN, USA). Mice were injected with 100-150 µCi (100 µl) of [18F] FDG into the tail vein prior to a 45min uninterrupted unilateral (right side) whisker stimulation (8–10 Hz, electrical toothbrush) followed by a 25min PET acquisition (15min emission/10min transmission scan using a [57Co] point source). Physiological parameters (body temperature, cardiac rate and respiration) were constantly monitored (Biopac Systems, Goleta, CA, USA), and remained stable throughout the experiment. The reconstruction of the functional metabolic images was generated based on a maximum a posteriori probability algorithm for the [18F] FDG standard uptake values (SUV) adjusted according to body weight, injected dose of radioligand and fasting glycemia measurements taken before and after the scanning for all animals. Images were linearly coregistered (7 parameters) on strain-specific magnetic resonance imaging (MRI) templates generated on a 7-T Bruker Pharmascan system (Bruker Biospin, Ettlingen, Germany) from similarly aged WT and A/T mice (n = 5 per group) (for details [14,21]). Image analysis was conducted with a platform based on minc toll kit available online at: http://www.bic.mni.mcgill.ca/ServicesSoftware/HomePage. The areas of interest for this study were drawn on the somatosensory cortices . Percentage activation was then defined as the metabolic index relative to the percentage of ([18F] FDG) SUV ratio between the maximally activated contralateral vs ipsilateral somatosensory cortex upon whisker stimulation. Final estimations were adjusted to animal body weight and injected radioactivity dose.
Cerebral blood flow (CBF)
CBF increases induced by unilateral (right side) whisker stimulation were measured using laser Doppler flowmetry (Transonic Systems Inc, Ithaca, NY) two days following the Morris watermaze (adult mice) or PET session (aged mice). Mice were anesthetised with a mixture of ketamine (85 mg/kg, intramuscularly (i.m.); Bioniche, Belleville, ON) and xylazine (3 mg/kg i.m.; Haver, Etobicoke, ON), and fixed in a stereotaxic frame. The bone over the left barrel cortex was thinned to translucency for positioning of the laser probe, as previously described . Body temperature was kept stable throughout the experiment with a heating pad. CBF was measured before, during and after whisker stimulation (4-5 stimulations, 8-10 Hz, 20s each interspaced by 1 min, electric toothbrush), and averaged for each mouse. Results are expressed as percentage increase of CBF from baseline. Experiments lasted ~20min/mouse, which allows for stable physiological parameters , and the experimenter was blind to the identity of the mouse.
Tissue collection and preparation
At the end of the in vivo testing, a subset of mice from both cohorts was sacrificed by cervical dislocation for functional reactivity studies of the middle cerebral artery (MCA) (see below). The remaining vessels of the circle of Willis with their cortical branches and attached pial membrane, together with cortex and hippocampus from one hemibrain were removed, frozen on dry ice and stored (-80° C) for subsequent ELISA and Western blot experiments. The other hemisphere was immersion-fixed (4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB), pH 7.4, overnight, 4° C), cryoprotected overnight (4° C in 30% sucrose 0.1 M PB), frozen in isopentane (-45° C) and stored (-80° C) until cutting of free-floating thick sections (25 µm) on a freezing-microtome. The remaining mice from each group were anesthetized with pentobarbital (80 mg/kg i.p.) and perfused transcardially with a 4% PFA solution. The brains were prepared as above, except that one hemisphere was processed for parafﬁn sectioning (5 µm-thick).
MCA segments (40–70 µm average intraluminal diameter) were cannulated, pressurized (60 mm Hg) and superfused with oxygenated Krebs solution (~37° C) for reactivity studies using online videomicroscopy . Dilatory responses to acetylcholine (ACh; 10-10-10-5 M), calcitonin gene-related peptide (CGRP; 10-10-10-6 M) were tested on vessels pre-constricted submaximally with serotonin (5-HT; 2×10-7 M). Contractile responses to endothelin-1 (ET-1; 10-10-10-6 M), 5-HT (10-10-10-6 M) and to inhibition of nitric oxide synthase (NOS) with Nω-nitro-L-arginine (L-NNA; 10-5 M; 35min) were tested on vessels at basal tone. In the adult cohort, responses to 5-HT (10-10-10-6 M) and NO donor sodium nitroprusside (SNP; 10-10-10-4 M) were also tested. Changes in vessel diameter from either the basal or pre-constricted tone were expressed in percentage and plotted as a function of agonist concentration or time course of L-NNA incubation. Agonist efficacy and potency were compared using the maximal response (EAmax) and half maximal effective agonist concentration [EC50 value or pD2=-(log EC50)], respectively.
ELISA measurement of Aβ1-40 and Aβ1-42
Soluble and insoluble Aβ1-40 and Aβ1-42 levels in cortex and hippocampus from hemibrains of adult and aged A/T mice were measured using an enzyme-linked immunosorbent assay (ELISA; BioSource International), as previously described . Results are expressed as micrograms per gram (µg/g) of protein in the supernatant (soluble Aβ species) or formic acid fractions (insoluble Aβ species).
Proteins extracted from cerebral cortex and hippocampus (~20µg) were loaded onto a 15% Tris/tricine SDS PAGE and transferred to nitrocellulose membranes. Total soluble Aβ levels were detected with a mouse anti-Aβ1-16 antibody (6E10, 1:1000, Covance, Emeryville, CA, USA). Levels of proteins involved in vascular function and structure were also assessed in pial vessel extracts. Proteins (12-15 µg) loaded onto 10% SDS PAGE were probed with the following antibodies: goat anti-connective tissue growth factor (CTGF; 1:400; Abcam, San Francisco, CA, USA), -matrix metalloproteinase 9 (MMP9; 1:2000; Millipore, Temecula, CA, USA), -cyclooxygenase-2 (COX-2; 1:200; Cayman, Ann Arbor, MI, USA), rabbit anti-vascular endothelial growth factor (VEGF; 1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or -actin (1:8000; Santa Cruz Biotechnology A5441, Santa Cruz, CA, USA). Membranes were incubated (1h) with horseradish peroxidase-conjugated secondary antibodies (1:2000; Jackson ImmunoResearch, West Grove, PA, USA), and visualized with Enhanced ChemiLuminescence (ECL Plus kit; Amersham, Baie d’Urfé, QC, Canada) using phosphorImager (Scanner STORM 860; GE Healthcare, Baie d’Urfé, QC, Canada). Quantification was performed with ImageQuant 5.0 (Molecular Dynamics, Sunnyvale, CA, USA).
Histochemical and Immunohistochemical stainings
Mature, dense core Aβ plaques were stained in 25µm-thick sections with 1% thioflavin S (8min). In similar sections, activated astrocytes and microglial cells were respectively immunodetected with a rabbit anti-GFAP antibody (1:1000; DAKO) or anti-ionized calcium binding adaptor molecule 1 (Iba-1; 1:300, Wako Chemicals, VA, USA), followed by a donkey anti-rabbit Cy2-conjugated secondary antibody (1:400; Jackson ImmunoResearch). Dewaxed thin paraffin sections (5 µm) were stained with 6E10 antibody to quantify total Aβ plaque load (1:2000). Sections were observed under a Leitz Aristoplan light microscope equipped with epifluorescence using an FITC filter (Leica). Pictures were taken with a Nikon digital camera (Coolpix 4500), and the percent area occupied by GFAP-, thioflavin S- and 6E10-positive immunostaining in cortex and/or hippocampus were quantified with MetaMorph 6.1r3 program (Universal Imaging).
Data are expressed as means ± SEM and were analyzed by two-way ANOVA with genotype and treatment as factors or repeated measures ANOVA, followed by Newman-Keuls post-hoc multiple comparison test (Statistica for Academia, Tulsa, OK, USA). P values were reported if the interaction or at least one factor was significant. Two-group comparisons were analyzed by Student’s t test (GraphPad Prism 4, San Diego, CA, USA). A p < 0.05 was significant.
Pioglitazone normalized neurovascular and neurometabolic coupling responses
The CBF response to increased neuronal activity induced by whisker stimulation was significantly reduced in adult (18.7±1.7%; p<0.01) and aged (18.3±1.2%; p<0.01) A/T mice compared to age-matched WT controls (adult: 24.6±2.0% and aged: 27.6±1.0%), as shown by the laser Doppler flowmetry curves (adult cohort) and peak of CBF responses in cohorts of both ages (Figure 1A). Similarly, in aged A/T mice, the selective increase in CGU induced by whisker stimulation in the contralateral somatosensory cortex was significantly less than in WT littermates (% activation ratio: 1.3 ± 1.1 vs 8.4 ± 1.7 respectively; p < 0.05) (Figure 1B). Pioglitazone normalized the evoked CBF response to increased neuronal activity in both adult and aged A/T mice to levels comparable to their control counterparts (Figure 1A). The CGU response was also significantly improved by pioglitazone in aged A/T mice (A/Tpio: 6.4 ± 1.3; Figure 1B). Treatment had no effect on WT controls for both responses.
A, The impaired hyperemic response to whisker stimulation in adult and aged A/T mice was rescued by pioglitazone compared to age-matched WT controls, as measured by LDF (n=4 mice/group) (traces of adult mice shown, green: WT; turquoise: WTpio; violet: A/T and pink: A/Tpio). Values represent the percent increase in CBF induced by whisker stimulation relative to baseline. B, Pioglitazone also improved the decreased CGU response to whisker stimulation in the somatosensory cortex of aged A/T compared to WT mice (n=3-6 mice/group). The % activation ratio denotes the percentage of corrected standard uptake value (SUV) in the activated contralateral (left side (L)) vs. ipsilateral (right side (R)) somatosensory cortex. Error bars represent SEM. ★p<0.05, ★★p<0.01, ★★★p<0.001 using two-way ANOVA followed by Newman-Keuls post-hoc test.
Pioglitazone did not rescue spatial learning and memory – target quadrant
Adult and aged A/T mice displayed significantly increased escape latencies in finding the hidden platform compared to treated and untreated WT mice (Figure 2A). A/T mice also had a decreased inclination for the target quadrant during the probe trial, as shown for the adult cohort by the reduced time spent in this quadrant (#4) and greater average distance to the platform location (Figure 2B). These changes are indicative of impaired spatial learning and memory compared to their age-matched WT controls. These deficits could not be explained by visual or motor disabilities as all groups had comparable swim speeds (data not shown) and similar abilities to find the visible platform (days 1-3, Figure 2A). Further analysis of the search patterns in slices of 15s (Figure 2C) revealed that WT controls focused on the target quadrant throughout the probe trial with minimal navigation elsewhere (including in the original quadrant 2) (Figure 2B), as also depicted by their representative swim patterns (Figure 2F). In contrast, A/T mice navigated less in the target quadrant as the percent of time spent (Figure 2B) or distance traveled (A/T 13.8±3.3% vs. WT 36.2±3.8%, p<0.01) in the target quadrant were significantly less than in WT controls. Average distance to the platform was also larger in A/T mice for the majority of the 15s segments (Figure 2C). Pioglitazone treatment did not improve performance of A/T mice of either age group during the learning phase or probe trial, as shown in the adult cohort (Figure 2A–C). Notably, spatial memory in adult and aged pioglitazone-treated WT mice was slightly, but significantly, deteriorated (p<0.05, Figure 2), an effect not seen in previous WT cohorts after shorter  or longer  treatment duration.
A, A/T mice (▼) displayed impaired learning during hidden-platform testing compared to aged-matched wild-type (WT) littermates (●) in the Morris watermaze. These deficits were not due to visual or motor disabilities as all groups had comparable abilities to find the visible platform (days 1-3). Pioglitazone did not improve the deficit in A/T mice (▽) and did not affect the performance of WT controls in the hidden platform training (days 4-8). (○).B, A/T mice, treated (▽) and non-treated (▼) with pioglitazone displayed significant deficit in memory retention as assessed during the probe trial in the target quadrant. C, When the probe trial was subdivided in 15s segments for better understanding of the pattern of behavior throughout the 60s-long probe trial in target quadrant, pioglitazone did not exert any benefit in A/T mice. D, A/T mice showed an inclination for the original quadrant during the probe trial, as shown by the increased time spent in this quadrant and smaller average distance to the platform location. E, Patterns of behaviour in original quadrant segmented in 4 slices of 15s each during the probe trial showed that pioglitazone had a positive effect in A/T mice (▽) in increasing percent time spent and average distance to platform during in the last quarter of the probe trial. F, Pie-representation of typical swimming patterns of % time spent and % distance traveled in target quadrant (red, #4) compared to the original quadrant (yellow, #2) during the probe trial. The drawings (on the left) are representations of single mouse swimming pattern best matching the average of of each group, as displayed by the pie patterns (on the right). Error bars represent SEM (n=6-9 mice/group). ★p<0.05 ★★, ** p<0.01, ★★★p<0.001 when compared to untreated WT controls (★) or A/T mice (*) using two-way ANOVA and repeated measures ANOVA followed by Newman-Keuls post-hoc test.
Pioglitazone and cognitive flexibility – original quadrant
In contrast to WT controls, both adult and aged A/T mice targeted the original quadrant (#2) throughout the probe trial, as shown here in adult mice by both increased percent time spent (Figure 2D) and distance traveled (WT 20.5±2.8% vs. A/T 42.6±4.5, p<0.01) in this quadrant. This persistence for the original platform location was apparent throughout most of the probe trial and was significant in the last 15s segmentation analysis for all parameters assessed including average distance from platform, percent time spent (Figure 2E), and distance travelled (WT 20.4±2.9% vs. A/T 54.7±8.8%, p<0.01). The preference of A/T mice for the original quadrant was obvious compared to all other quadrants, including the target quadrant (Figure 2F).
In adult, but not aged (data not shown), A/T mice pioglitazone had a positive effect in decreasing their time spent in the original quadrant and the average distance to platform (Figure 2D), specifically in the last quarter of the probe trial (Figure 2E). Similarly, the pioglitazone-treated adult A/T spent significantly less time (Figure 2E) and traveled less distance (A/T 42.6±4.5% vs. A/Tpio 24.5±5.2%, p<0.01) in the original quadrant during the last 15s-segment relative to untreated A/T mice. However, although their search towards the target quadrant was slightly improved, it was not complete since pioglitazone-treated mice predominantly explored in quadrant 3, as seen by their swimming patterns (Figure 2F). Hence, pioglitazone allowed for the treated-A/T mice to unlearn the original location of the visible platform without granting them the capacity to remember the new location of the hidden platform.
Pioglitazone effects on brain vessel reactivity and fibrosis
In agreement with our previous study , adult and aged A/T mice displayed significantly decreased dilatory responses to ACh and CGRP compared to their age-matched WT controls (Tables 1 and 2), as illustrated in the adult group (Figure 3A). Reduced diameter decrease during NOS inhibition with L-NNA was also observed in A/T mice of both age groups, confirming a diminished constitutive NO synthesis. Despite these alterations in vascular reactivity, receptor desensitization was ruled out, as the agonist potencies at vascular receptors were strictly comparable between all groups (Tables 1 and 2). Arterial relaxation to the NO donor SNP and the constriction induced by ET-1 were normal in A/T mice, indicative of preserved contractile capacity, as also supported by the unaltered pre-constriction response to 5-HT (tested in the adult cohort only) (Figure 3A). Pioglitazone treatment partially (aged) or fully (adult) restored constitutive NO synthesis in A/T mice (Figure 3A, Tables 1, 2), and did not alter the contractile responses to 5-HT and ET-1. However, pioglitazone significantly deteriorated the dilatory responses to ACh and CGRP, resulting in no dilatation and weak contractile responses at high agonist concentrations (Figure 3A). Similarly, the NO donor SNP elicited vasoconstrictions at low doses that reverted to dilatations at higher concentrations (Figure 3A). These worsened responses were observed in both adult (Figure 3A, Table 1) and aged (Table 2) pioglitazone-treated A/T mice, although they were less pronounced in the adult cohort. Pioglitazone did not alter the cerebrovascular reactivity of WT mice (Figure 3A). The cerebrovascular levels of the prostaglandin-synthesizing enzyme COX-2, a vasodilator synthesizing enzyme (Figure 3B)  and of the pro-fibrotic proteins CTGF, VEGF or MMP9 [26,27] were not altered by genotype or treatment, as shown in the adult cohort (Figure 3B). These findings suggest that dysfunctions are not primarily caused by structural changes of the vessel wall.
|ACh||EAmax||51.2 ± 2.5||46.7 ± 4.0||23.7±3.6★★★||- 3.1± 3.6★★★,***|
|pD2||8.4 ± 0.2||7.9 ± 0.2||7.7 ± 0.4||ND|
|CGRP||EAmax||57.6 ± 2.0||54.0 ± 3.6||31.9 ± 3.2★★★||- 0.4 ± 2.0★★★,***|
|pD2||8.0 ± 0.1||8.0 ± 0.2||8.2 ± 0.2||ND|
|SNP||EAmax||62.0 ± 6.1||56.1 ± 3.0||59.5 ± 3.2||15.5 ± 10.1|
|5-HT||EAmax||14.6 ± 0.2||14.2 ± 0.5||13.5 ± 1.3||14.3 ± 1.2|
|ET-1||EAmax||52.3 ± 2.4||33.8 ± 4.1||44.9 ± 7.5||36.1 ± 5.0|
|pD2||7.6 ± 0.1||7.8 ± 0.3||8.0 ± 0.5||7.9 ± 0.4|
|L-NNA||EAmax||43.7 ± 0.1||32.7 ± 1.9||21.8 ± 3.7★★★||32.8 ± 11.1*|
|ACh||EAmax||52.7 ± 2.0||54.5 ± 2.4||26.0±1.3★★★||16.0 ± 2.2★★★,***|
|pD2||8.4 ± 0.1||8.3 ± 0.1||8.0 ± 0.1||ND|
|CGRP||EAmax||54.1 ± 1.6||55.6 ± 3.0||25.3 ± 1.4★★★||9.9 ± 2.1★★★,***|
|pD2||8.8 ± 0.1||8.4 ± 0.1||8.3 ± 0.1||ND|
|ET-1||EAmax||58.3 ± 5.0||42.7 ± 3.6||53.4 ± 3.8||45.7 ± 4.0|
|pD2||8.2 ± 0.2||8.3 ± 0.3||8.4 ± 0.2||8.2 ± 0.2|
|L-NNA||EAmax||52.3 ± 0.5||53.5 ± 5.1||15.1 ± 1.0★★★||28.7 ± 6.3★★|
A, The impaired cerebrovascular dilatations to acetylcholine (ACh) and calcitonin gene-related peptide (CGRP) in A/T mice (▼) were aggravated or reversed to weak constrictions by pioglitazone (▽). This was accompanied by a full recovery of baseline NO synthesis in adult A/T mice measured during NOS inhibition (L-NNA, 10-5M). Dilatations induced by the NO donor SNP were unimpaired in A/T mice, but were reversed to small constrictions or shifted to the right at high SNP concentrations in pioglitazone-treated A/T mice. Contractile responses to 5-HT and ET-1 were unaltered in A/T mice and pioglitazone had no detrimental effects. Error bars represent SEM (n=3-6 mice/group). B, Vasodilator synthesizing enzyme COX-2 and proteins associated with vascular fibrosis VEGF, CTGF and MMP-9 were not significantly altered by genotype or treatment, as measured by Western blot in pial vessels of adult A/T mice relative to their treated counterparts and WT mice. Actin was used as a reference for loading (n=4 mice/group). Similar results were obtained in the aged cohort, but data were not illustrated for clarity purposes. Error bars represent SEM. ★p<0.05, ★★, ** p<0.01, ★★★, *** p<0.001 when compared to untreated WT controls (★) or A/T mice (*) using two-way ANOVA (part A) and repeated measures ANOVA (part B) followed by Newman-Keuls post-hoc test.
Pioglitazone and amyloidosis
Pioglitazone had no effect on soluble and insoluble Aβ1-40 and Aβ1-42 levels measured by ELISA in cortex and hippocampus of adult (Figure 4A) and aged (data not shown) A/T mice. High total soluble Aβ levels were also detected in cortex and hippocampus of adult and aged A/T mice by Western blot and, similarly, pioglitazone had no benefit at either age, as shown in cortex of adult A/T mice (Figure 4B). Plaque load of thioflavin S-positive dense core plaques was unaltered by pioglitazone in cortex and hippocampus from A/T mice irrespective of age and length of treatment (Figure 4C). This was further confirmed by the unaltered load of diffuse and dense core 6E10-immunopositive Aβ plaques measured in thin sections (Figure 4D). Together, these results demonstrate that pioglitazone does not counter the amyloid pathology in A/T mice, in line with previous studies in singly APP mice [10,12].
A, Levels of soluble and insoluble Aβ1-40 and Aβ1-42 in adult A/T mice, as assayed in cortex and hippocampus by ELISA, were comparable between pioglitazone-treated- and untreated A/T mice. B, Western blot analysis with 6E10 antibody confirmed no effect of pioglitazone on soluble Aβ species in cortex of adult A/T mice. On the gel, (★) represents the APP band and (*), the 4kDa band of monomeric Aβ including Aβ1-40 and Aβ1-42, as quantified in the bar graph. C, Thioflavin S-stained dense-core Aβ plaque load in cortex and hippocampus were unaltered by pioglitazone in adult A/T mice. D, Similarly, 6E10-immunostaining of diffuse and dense-core Aβ plaques in 5µm-thick paraffin sections showed no effect of pioglitazone on cortical and hippocampal Aβ plaque load in adult A/T mice. Error bars represent SEM. ★p<0.05, ★★p<0.01, ★★★p<0.001 for comparison to A/T mice using two-way ANOVA followed by Newman-Keuls post-hoc test (n=4 mice/group).
Pioglitazone and neuroinflammation
Both adult and aged A/T mice exhibited a significant increase in GFAP-positive area in cortex and hippocampus compared to their age-matched WT controls (p<0.001) (adult cohort, Figure 5A, B). In both cohorts, pioglitazone significantly reduced astroglial activation only in the cortex where activation was not as severe as in the hippocampus (Figure 5B). Microglia were also activated as evidenced by the percent area occupied by and intensity of Iba-1-immunstained microglial cells in the hippocampus but not in the cortex of A/T mice of both ages compared WT controls (Figure 6A, B). Pioglitazone exerted significant protective effects in minimizing microglial activation in the hippocampus of A/T mice (Figure 6 A, B).
A, In the cortex (but not in the hippocampus) of aged A/T mice, pioglitazone significantly reduced the increase in GFAP-immunoreactive (IR) surface area relative to WT controls (n=4 mice/group). B, GFAP analysis of both the aged and adult groups rendered the same results of a selective cortical effect of pioglitazone on astroglial activation. Scale bar = 300 µm and 100 µm (insert). Error bars represent SEM. ★p<0.05, ★★p<0.01, ★★★p<0.001 using two-way ANOVA followed by Newman-Keuls post-hoc test.
A, Pioglitazone significantly reduced the increased surface area of Iba-1-immunolabelled microglial cells in the hippocampus of both aged and adult A/T mice compared to WT controls, as shown in the aged group. B, Both the area occupied by and staining intensity of Iba-1-positive microglial cells in the hippocampus were reduced by pioglitazone at both ages. No effect was seen in the cortex (n=4 mice/group). Scale bar = 100 µm and 25 µm (insert). Error bars represent SEM. ★p<0.05, ★★p<0.01 using two-way ANOVA followed by Newman-Keuls post-hoc test.
This study demonstrates positive effects of pioglitazone on neurometabolic and neurovascular coupling responses, and on neuroinflammation in a mouse model that recapitulates the AD-related Aβ pathology, cognitive deficits and cerebrovascular alterations. A modest improvement in reversal learning, suggesting improved cognitive flexibility (i.e., less perseveration) was also observed in the adult, but not in the aged cohort, notwithstanding persistent memory deficits and amyloidosis in both age groups. However, the contractile effect of pioglitazone on brain vessels of A/T mice pointed to possible detrimental effects in AD patients with vascular diseases.
Pioglitazone on neurometabolic and neurovascular coupling responses
Early decreases in resting CGU have been reported in the parietotemporal and posterior cingulate cortex in AD patients [28–30] and in various cortical areas in APP mice  using FDG-PET and autoradiography, respectively. Altered neurometabolic coupling in response to increased neuronal activity has also been reported in AD patients , APP mice  and aged A/T mice . The finding that pioglitazone improved CGU during activation of the somatosensory cortex in the combined Aβ- and TGF-β1-burdened brain of aged A/T mice underscored the high efficacy of pioglitazone in restoring brain glucose metabolism. In vivo experiments in healthy rat brain showed that glucose preferentially fuels astrocytes during neuronal activity even though neurons have greater metabolic needs . Astrocytes then supply neurons with glycolytic products, particularly lactate, for use in oxidative metabolism . Hence, our FDG-PET results may reflect both restored astrocytic glucose metabolic activity and neuronal oxidative metabolism by pioglitazone, similar to what has been demonstrated in vitro [35,36]. In support of the normalized astrocytic function by pioglitazone is our finding of reduced cortical GFAP-immunostaining intensity, a marker of increased astrocytic-reactive inflammatory response . An achieved astroglial homeostasis could also explain the normalization of the functional hyperemic response that requires the concerted action of neurons, astrocytes and vascular cells [38,39]. Particularly, PPARγ activation may have facilitated the ability of astrocytes to synthesize arachidonic acid derivatives such as vasodilatory epoxyeicosatrienoic acids (EETs) that mediate a large part of the neurovascular coupling response to whisker stimulation [25,40], a response severely affected in both APP and A/T mice [5,41]. However, the pioglitazone-mediated anti-inflammatory properties evidenced by the silencing of cortical astrocytes and hippocampal microglial cells that are thought to participate in the clearance of aggregated Aβ species , did not impact on either soluble Aβ species or Aβ plaque load. This finding is in line with some studies in APP mice [10,12], but not with others that reported decreased plaque load or Aβ processing [11,43] following pioglitazone treatment.
Pioglitazone and spatial memory
Despite the beneficial effects of pioglitazone highlighted above, spatial learning and memory in adult or aged A/T mice was not improved, as in our previous findings in aged APP mice . This may indicate that, despite hypoperfusion [44,45] and hypometabolism  being good correlates of memory decline in AD, local recovery of CBF and CGU responses in the somatosensory cortex of pioglitazone-treated A/T mice are not good indicators of changes in hippocampus-based mnemonic function. Based on the heterogeneity in brain glucose metabolism, pioglitazone may have failed to normalize the metabolic deficit in the limbic system in A/T mice, as previously reported in TGF mice . Indeed, in contrast to its beneficial effects in cortex, pioglitazone did not reduce astrocytic activation in the hippocampus. Since astrocytes are important in maintaining hippocampal homeostasis that is critical for memory formation , we suggest that their persistent activated state might contribute to the lack of memory rescue in treated A/T mice. Future investigations should ideally evaluate the evoked CGU or CBF responses in the hippocampus, and use hippocampus-specific stimulation paradigms that would better correlate with memory performances.
In a study on a small population of mild AD patients with type II diabetes treated with pioglitazone, resting CBF improvement in the parietal lobe – including the post-central gyrus (encompassing the somatosensory cortex) – was accompanied by cognitive improvement . This beneficial effect was also concurrent with an increase in insulin-mediated glucose uptake , a known mechanism of action for PPARγ . However, aside from one additional study showing cognitive improvement in diabetic AD patients with pioglitazone , all other clinical trials of AD patients failed to demonstrate benefit . It is thus tempting to speculate that pioglitazone may confer cognitive protection only in AD patients with diabetes.
Pioglitazone and cognitive flexibility
Our data demonstrated that A/T mice exhibited a moderate preference for the original quadrant during the probe trial, as opposed to the target quadrant. Our protocol consisted of a single visible-to-hidden platform relocation and, as such, was less robust than the memory flexibility test of Chen and colleagues who used a series of hidden-platform relocation trials for the measurement of hippocampal-based learning deficits . Nevertheless, our data show that pioglitazone exerted beneficial effects on the impaired reversal learning of A/T mice. Pioglitazone facilitated their ability to “switch” from a perseverative (and incorrect) strategy in exploring in the original quadrant, to new strategies in relocating the hidden platform of the target quadrant, and this, only in the adult cohort. These positive results point to age and treatment duration being both important elements in this beneficial effect of pioglitazone. Interestingly, rosiglitazone, another PPARγ agonist, similarly enhanced cognitive flexibility in APP/PS1 mice . Hence, this new therapeutic potential uncovered for pioglitazone in adult A/T mice may bear clinical significance for AD patients in light of their reported impaired reversal learning . Yet, a therapeutic benefit may be highly dependent on the stage of the disease and time of treatment initiation.
Pioglitazone and cerebrovascular reactivity
Recovery of cerebrovascular reactivity with pioglitazone was anticipated based on its proven benefit in aged APP  and TGF  mice. Whereas vasoconstriction to ET-1 and 5-HT remained unaffected, indicative of preserved smooth muscle integrity, the impaired ACh- and CGRP-mediated dilations in A/T brain vessels were aggravated or reversed to small constrictions after pioglitazone treatment. This worsening behavior might relate to the ability of pioglitazone to directly elicit concentration-dependent dilations through endothelium-mediated NO release and gyanylyl cyclase activation, as evidenced in retinal arteries  or aorta . Additionally, the ability of pioglitazone to inhibit ATP-sensitive K+ (KATP) channels, as shown in the coronary circulation  may explain its adverse effects on CGRP-induced dilations that are largely mediated by KATP channels [55–57]. Although less involved in CGRP-mediated relaxation , the activation of smooth muscle voltage gated K+ (Kv) channels by pioglitazone  may also have contributed to its worsening effect. It thus appears that chronic pioglitazone treatment in A/T mice hindered the NO signaling cascade or K+ channel activation required for ACh- and CGRP-mediated dilatations [55–57]. This possibility is reinforced by the failure of the NO donor SNP to induce dilation, pointing to mechanisms downstream of NO production. The finding that baseline NO production was not altered by pioglitazone further points to dysfunction in NO signaling. However, we cannot exclude that cerebral amyloid angiopathy (CAA), which is accrued in A/T mice compared to APP mice , contributed to the altered reactivity through other mechanisms . Although less potent at inhibiting KATP channels than rosiglitazone , another PPARγ agonist recently prohibited from use in diabetic patients for its high-risk cardiovascular profile , our findings point to potential deleterious effects of pioglitazone on cerebral dilatory function.
Our results show that pioglitazone exerts beneficial effects in A/T mice with multiple AD hallmarks. Pioglitazone countered cortical neuroinflammation, neurometabolic and neurovascular coupling responses to increased neuronal activity in sensory pathways, with an age-dependent improvement in reversal learning, pointing to benefits at several levels of the AD pathology and to potential use as a combined therapy. However, the A/T mouse model unmasked previously unrecognized, possibly deleterious, effect of chronic pioglitazone therapy on dilatory function, particularly those involving NO signaling. This finding may be relevant to AD patients with comorbid cardiovascular diseases despite the better cardiovascular safety profile of pioglitazone compared to rosiglitazone [62,63].
We thank Dr. L. Mucke (Gladstone Institute of Neurological Disease and Department of Neurology, UCSF, CA) and the J. David Gladstone Institutes for providing us hAPPSwe,Ind and TGF-β1 transgenic mouse breeders, Mr A. Aliaga for the PET scans, Mr J. Cakiroglu and Dr. B. Bedell (Small Animal Imaging Laboratory, SAIL, Montreal Neurological Institute) for generating the MRI templates. We extend our gratitude to Drs. X.-K. Tong and N. Nicolakakis for their invaluable technical training and support, and Ms. P. Fernandes for the laser Doppler flowmetry experiments.
Conceived and designed the experiments: EH PP. Performed the experiments: PP. Analyzed the data: PP PRN JR EH. Wrote the manuscript: PP EH.
- 1. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 118: 103-113. doi:10.1007/s00401-009-0522-3. PubMed: 19319544.
- 2. Grammas P, Ovase R (2002) Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer’s disease brain. Am J Pathol 160: 1583-1587. doi:10.1016/S0002-9440(10)61105-4. PubMed: 12000710.
- 3. Tesseur I, Wyss-Coray T (2006) A role for TGF-beta signaling in neurodegeneration: evidence from genetically engineered models. Curr Alzheimer Res 3: 505-513. doi:10.2174/156720506779025297. PubMed: 17168649.
- 4. Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E (2000) Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am J Pathol 156: 139-150. doi:10.1016/S0002-9440(10)64713-X. PubMed: 10623661.
- 5. Ongali B, Nicolakakis N, Lecrux C, Aboulkassim T, Rosa-Neto P et al. (2010) Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer’s disease. Am J Pathol 177: 3071-3080. doi:10.2353/ajpath.2010.100339. PubMed: 21088218.
- 6. Zlokovic BV (2010) Neurodegeneration and the neurovascular unit. Nat Med 16: 1370-1371. doi:10.1038/nm1210-1370. PubMed: 21135839.
- 7. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011) A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68: 45-50. doi:10.1001/archneurol.2010.229. PubMed: 20837824.
- 8. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H et al. (2011) Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32: 1626-1633. doi:10.1016/j.neurobiolaging.2009.10.009. PubMed: 19923038.
- 9. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M et al. (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47: 29-35. PubMed: 9037440.
- 10. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R et al. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J Neurosci 23: 7504-7509. PubMed: 12930788.
- 11. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I et al. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128: 1442-1453. doi:10.1093/brain/awh452. PubMed: 15817521.
- 12. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P et al. (2008) Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28: 9287-9296. doi:10.1523/JNEUROSCI.3348-08.2008. PubMed: 18784309.
- 13. Gaertner RF, Wyss-Coray T, Von Euw D, Lesné S, Vivien D et al. (2005) Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer’s disease-like cerebrovascular abnormalities. Neurobiol Dis 19: 38-46. doi:10.1016/j.nbd.2004.11.008. PubMed: 15837559.
- 14. Nicolakakis N, Aboulkassim T, Aliaga A, Tong XK, Rosa-Neto P et al. (2011) Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: Recovery with pioglitazone. J Cereb Blood Flow Metab 31: 200-211. doi:10.1038/jcbfm.2010.78. PubMed: 20571524.
- 15. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM et al. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058. PubMed: 10818140.
- 16. Deipolyi AR, Fang S, Palop JJ, Yu GQ, Wang X et al. (2008) Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging 29: 253-266. doi:10.1016/j.neurobiolaging.2006.10.021. PubMed: 17126954.
- 17. Gallagher M, Burwell R, Burchinal M (1993) Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 107: 618-626. doi:10.1037/0735-7044.107.4.618. PubMed: 8397866.
- 18. Maei HR, Zaslavsky K, Teixeira CM, Frankland PW (2009) What is the Most Sensitive Measure of Water Maze Probe Test Performance? Front Integr Neurosci 3: 4. PubMed: 19404412.
- 19. Chen G, Chen KS, Knox J, Inglis J, Bernard A et al. (2000) A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer’s disease. Nature 408: 975-979. doi:10.1038/35050103. PubMed: 11140684.
- 20. Seeger T, Fedorova I, Zheng F, Miyakawa T, Koustova E et al. (2004) M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 24: 10117-10127. doi:10.1523/JNEUROSCI.3581-04.2004. PubMed: 15537882.
- 21. Tong XK, Lecrux C, Rosa-Neto P (2012) Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits. J Neurosci 32: 4705-4715. doi:10.1523/JNEUROSCI.0169-12.2012. PubMed: 22492027.
- 22. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. xxii. San Diego: Academic Press. p. 186. of plates p.
- 23. Tong XK, Nicolakakis N, Kocharyan A, Hamel E (2005) Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer’s disease. J Neurosci 25: 11165-11174. doi:10.1523/JNEUROSCI.4031-05.2005. PubMed: 16319316.
- 24. Nicolakakis N, Hamel E (2011) Neurovascular function in Alzheimer’s disease patients and experimental models. J Cereb Blood Flow Metab 31: 1354-1370. doi:10.1038/jcbfm.2011.43. PubMed: 21468088.
- 25. Niwa K, Haensel C, Ross ME, Iadecola C (2001) Cyclooxygenase-1 participates in selected vasodilator responses of the cerebral circulation. Circ Res 88: 600-608. doi:10.1161/01.RES.88.6.600. PubMed: 11282894.
- 26. Lipson KE, Wong C, Teng Y, Spong S (2012) CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 5 Suppl 1: S24. doi:10.1186/1755-1536-5-S1-S24. PubMed: 23259531.
- 27. Lan TH, Huang XQ, Tan HM (2013) Vascular fibrosis in atherosclerosis. Cardiovasc Pathol. PubMed: 23375582.
- 28. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J et al. (1994) Altered cerebral energy metabolism in Alzheimer’s disease: a PET study. J Nucl Med 35: 1-6. PubMed: 8271029.
- 29. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B et al. (2004) MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63: 2332-2340. doi:10.1212/01.WNL.0000147469.18313.3B. PubMed: 15623696.
- 30. Langbaum JB, Chen K, Lee W, Reschke C, Bandy D et al. (2009) Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neuroimage 45: 1107-1116. doi:10.1016/j.neuroimage.2008.12.072. PubMed: 19349228.
- 31. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C (2002) Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 9: 61-68. doi:10.1006/nbdi.2001.0460. PubMed: 11848685.
- 32. Melrose RJ, Campa OM, Harwood DG, Osato S, Mandelkern MA et al. (2009) The neural correlates of naming and fluency deficits in Alzheimer’s disease: an FDG-PET study. Int J Geriatr Psychiatry 24: 885-893. doi:10.1002/gps.2229. PubMed: 19296551.
- 33. Chuquet J, Quilichini P, Nimchinsky EA, Buzsáki G (2010) Predominant enhancement of glucose uptake in astrocytes versus neurons during activation of the somatosensory cortex. J Neurosci 30: 15298-15303. doi:10.1523/JNEUROSCI.0762-10.2010. PubMed: 21068334.
- 34. Pellerin L, Magistretti PJ (2003) How to balance the brain energy budget while spending glucose differently. J Physiol 546: 325. doi:10.1113/jphysiol.2002.035105. PubMed: 12527720.
- 35. Izawa Y, Takahashi S, Suzuki N (2009) Pioglitazone enhances pyruvate and lactate oxidation in cultured neurons but not in cultured astroglia. Brain Res 1305: 64-73. doi:10.1016/j.brainres.2009.09.098. PubMed: 19800324.
- 36. Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP et al. (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278: 5828-5836. doi:10.1074/jbc.M208132200. PubMed: 12486128.
- 37. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12: 1005-1015. PubMed: 16960575.
- 38. Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA et al. (2003) Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci 6: 43-50. doi:10.1038/nn980. PubMed: 12469126.
- 39. Koehler RC, Roman RJ, Harder DR (2009) Astrocytes and the regulation of cerebral blood flow. Trends Neurosci 32: 160-169. doi:10.1016/j.tins.2008.11.005. PubMed: 19162338.
- 40. Lecrux C, Hamel E (2011) The neurovascular unit in brain function and disease. Acta Physiol (Oxf) 203: 47-59. doi:10.1111/j.1748-1716.2011.02256.x. PubMed: 21272266.
- 41. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA et al. (2001) A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281: H2417-H2424. PubMed: 11709407.
- 42. Rivest S (2011) The promise of anti-inflammatory therapies for CNS injuries and diseases. Expert Rev Neurother 11: 783-786. doi:10.1586/ern.11.64. PubMed: 21651326.
- 43. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T et al. (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23: 9796-9804. PubMed: 14586007.
- 44. de la Torre JC (1999) Critical threshold cerebral hypoperfusion causes Alzheimer’s disease? Acta Neuropathol 98: 1-8. doi:10.1007/s004010051044. PubMed: 10412794.
- 45. Farkas E, Luiten PG (2001) Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol 64: 575-611. doi:10.1016/S0301-0082(00)00068-X. PubMed: 11311463.
- 46. Galea E, Feinstein DL, Lacombe P (2006) Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer’s disease and decreases it in wild-type mice. Diabetologia 49: 2153-2161. doi:10.1007/s00125-006-0326-0. PubMed: 16830140.
- 47. Santello M, Volterra A (2010) Neuroscience: Astrocytes as aide-mémoires. Nature 463: 169-170. doi:10.1038/463169a. PubMed: 20075911.
- 48. Nicolakakis N, Hamel E (2010) The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer’s Disease. Front Aging Neurosci 2: ([MedlinePgn:]) PubMed: 20725514.
- 49. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T (2009) Pioglitazone improved cognition in a pilot study on patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 57: 177-179. doi:10.1111/j.1532-5415.2009.02067.x. PubMed: 19170800.
- 50. Toledo EM, Inestrosa NC (2010) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease. Mol Psychiatry 15: 228-285.10.1038/mp.2009.72. PubMed: 19621015.
- 51. Levy-Gigi E, Kelemen O, Gluck MA, Kéri S (2011) Impaired context reversal learning, but not cue reversal learning, in patients with amnestic mild cognitive impairment. Neuropsychologia 49: 3320-3326. doi:10.1016/j.neuropsychologia.2011.08.005. PubMed: 21856321.
- 52. Omae T, Nagaoka T, Tanano I, Yoshida A (2011) Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, induces dilation of isolated porcine retinal arterioles: Role of nitric oxide and potassium channels. Invest Ophthalmol Vis Sci 52: 6749-6756. doi:10.1167/iovs.10-6826. PubMed: 21757589.
- 53. Nomura H, Yamawaki H, Mukohda M, Okada M, Hara Y (2008) Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel. J Pharmacol Sci 108: 258-265. doi:10.1254/jphs.08117FP. PubMed: 18987433.
- 54. Yu L, Jin X, Yang Y, Cui N, Jiang C (2011) Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline. Br J Pharmacol 164: 2064-2072. doi:10.1111/j.1476-5381.2011.01539.x. PubMed: 21671900.
- 55. Kitazono T, Heistad DD, Faraci FM (1993) Role of ATP-sensitive K+ channels in CGRP-induced dilatation of basilar artery in vivo. Am J Physiol 265: H581-H585. PubMed: 8368361.
- 56. Mathie RT, Ralevic V, Alexander B, Burnstock G (1991) Nitric oxide is the mediator of ATP-induced dilatation of the rabbit hepatic arterial vascular bed. Br J Pharmacol 103: 1602-1606. doi:10.1111/j.1476-5381.1991.tb09834.x. PubMed: 1884115.
- 57. Tong XK, Nicolakakis N, Fernandes P, Ongali B, Brouillette J et al. (2009) Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis 35: 406-414. doi:10.1016/j.nbd.2009.06.003. PubMed: 19524673.
- 58. Vedernikov YP, Fulep EE, Saade GR, Garfield RE (2002) Calcitonin gene-related peptide dilates the pregnant rat uterine vascular bed via guanylate cyclase, ATP- and Ca-sensitive potassium channels and gap junctions. Curr Med Res Opin 18: 465-470. doi:10.1185/030079902125001001. PubMed: 12564657.
- 59. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M et al. (2001) TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 7: 612-618. doi:10.1038/87945. PubMed: 11329064.
- 60. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH et al. (2008) Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci 28: 13542-13550. doi:10.1523/JNEUROSCI.4686-08.2008. PubMed: 19074028.
- 61. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH (2010) Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. J Am Coll Cardiol 55: 1885-1894. doi:10.1016/j.jacc.2010.02.014. PubMed: 20413044.
- 62. Ciudin A, Hernandez C, Simó R (2012) Update on Cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. Curr Top Med Chem, 12: 585–604. PubMed: 22242856.
- 63. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298: 1180-1188. doi:10.1001/jama.298.10.1180. PubMed: 17848652.